{"title": "FLULAVAL QUADRIVALENT (Influenza Vaccine) | GSK Flu", "author": null, "url": "https://gskflu.com/flulaval-quadrivalent/", "hostname": "gskflu.com", "description": "Learn more about FLULAVAL QUADRIVALENT. Access information on dosing & coding, immunogenicity, and more.", "sitename": "gskflu.com", "date": "2022-01-01", "cleaned_text": "Children aged 3 through 17 years In a clinical trial in subjects aged 3 through 17 years, FLULAVAL QUADRIVALENT (n=878) exhibited immunogenicity noninferior to two comparator trivalent inactivated influenza vaccine (TIV) formulations, each containing an influenza type B virus that corresponded to one of the two B viruses in FLULAVAL QUADRIVALENT, a type B virus of the Victoria lineage (TIV-1, n=871) or a type B virus of the Yamagata lineage (TIV-2, n=878). - Noninferiority was based on adjusted GMTs and seroconversion rates1 - Seroconversion was defined as a 4-fold increase over baseline in hemagglutination inhibition (HI) antibody from "}